05.08.2024 13:22:26
|
Fennec Pharma Names Hackman CEO
(RTTNews) - Monday, Fennec Pharmaceuticals Inc. (FENC) announced the appointment of Jeffrey Hackman as chief executive officer and Board member, effective August 16, 2024.
Rosty Raykov, CEO since 2009, will continue to serve on the Board.
The company indicated that Hackman's appointment is intended to further the development of PEDMARK, the sole approved treatment in the U.S. designed to minimize the risk of cisplatin-induced ototoxicity in pediatric cancer patients.
Hackman brings over 30 years of experience in commercial leadership including 12 years in oncology, and has led more than 10 product launches and successfully brought products to market relevant to PEDMARK.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Adherex Technologies Incmehr Nachrichten
09.03.25 |
Ausblick: Adherex Technologies veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
06.11.24 |
Ausblick: Adherex Technologies gewährt Anlegern Blick in die Bücher (finanzen.net) |
Analysen zu Adherex Technologies Incmehr Analysen
Aktien in diesem Artikel
Adherex Technologies Inc | 5,90 | -1,67% |
|